Beruflich Dokumente
Kultur Dokumente
S89
L. Therapeutic procedures
L1
A 4 years follow up in children with moderate/severe asthma
after discontinuation of 1 year treatment with omalizumab
C.E. Baena-Cagnani1 , A. Teijeiro1 , H. Badellino1 , M.E. Zernotti1 ,
G.W. Canonica2 , V.H. Croce1 , R. Baena-Cagnani1 . 1 CIMER Research
Center of Respiratory Medicine, Cordoba, Argentina; 2 Genoa University,
Allergy and Respiratory Medicine, Genoa, Italy
Background: Asthma guidelines include omalizumab in the step
up management in those patients with moderate/severe noncontrolled asthma despite the use of the highest dose recommended
treatment. This communication describes the 4 year follow up of